FDA Category 1 Peptides and the Opportunity for Community Pharmacies

Over the past two years, the regulatory conversation around peptides has intensified. In 2023, the FDA placed 19 peptides into Category 2 on the 503A bulk substances list, which effectively restricted their use in traditional pharmacy compounding.

However, recent policy discussions suggest that approximately 14 of these peptides may be moved to Category 1, meaning they would once again be recognized as substances that may be used in compounding while the FDA continues its formal evaluation.

For community pharmacies and compounding pharmacies, this shift represents a meaningful opportunity.

Demand for peptide-based therapies has not disappeared. In fact, interest has expanded across metabolic health, regenerative medicine, dermatology, neurocognitive support, immune modulation, and anti-aging medicine.

When regulated pharmacy access disappears, demand often moves toward unregulated research chemical markets, which lack quality oversight, chain of custody verification, and pharmacist supervision.

Allowing these peptides under Category 1 restores an important pathway:

• Physician-directed prescribing• Patient-specific compounding by licensed pharmacies• Verified APIs with Certificates of Analysis• Pharmacist oversight and safety controls

For community pharmacies, this represents both a clinical opportunity and a business opportunity to expand services into personalized medicine.

Understanding FDA Category 1 in 503A Compounding

Under Section 503A of the FD&C Act, pharmacies may compound medications using bulk drug substances that fall into three regulatory groups.

Category 1Bulk substances under review but currently permitted for compounding.

Category 2Substances with identified safety concerns or not permitted for compounding.

Category 3Substances with insufficient information for evaluation.

When a substance moves to Category 1, pharmacies may compound it for an individual patient with a valid prescription, provided they meet requirements such as:

• USP <795> non-sterile or USP <797> sterile standards• API sourced from FDA-registered manufacturers• Certificates of Analysis verification• Patient-specific prescriptions• State board of pharmacy compliance

This creates a framework where pharmacists and physicians remain central to therapy management.

Peptides Potentially Returning to Category 1

The peptides most frequently cited in discussions about a move to Category 1 include:

1. BPC-157

2. Thymosin Alpha-1

3. Thymosin Beta-4 Fragment (TB-500)

4. AOD-9604

5. GHK-Cu

6. Epitalon

7. KPV

8. MOTS-C

9. Semax

10. Selank

11. Kisspeptin-10

12. GHRP-6

13. Emideltide (DSIP)

14. PEG-MGF

Each of these peptides has different therapeutic applications and compounding considerations.

Clinical Applications and Compounding Opportunities

BPC-157

Primary uses

• Tissue healing• Tendon and ligament repair• GI mucosal healing• Anti-inflammatory effects

Potential patients

• Sports injuries• Orthopedic recovery• Inflammatory bowel conditions

Common compounded dosage forms

• Subcutaneous injections• Oral capsules• Topical creams or gels for localized injury

Typical compounded strengths

• 200 mcg – 500 mcg per injection• 250 mcg – 500 mcg capsules• 0.5% – 1% topical formulations

Thymosin Alpha-1 (TA-1)

Primary uses

• Immune system modulation• Viral infection support• Oncology supportive care

Potential patients

• Chronic viral infections• Immunocompromised individuals• Immune support protocols

Compounded dosage forms

• Subcutaneous injection

Typical strengths

• 1 mg to 1.6 mg per injection• 2–3 injections per week depending on protocol

Thymosin Beta-4 Fragment (TB-500)

Primary uses

• Tissue repair• Muscle recovery• Wound healing

Potential patients

• Athletic injuries• Post-surgical recovery• Chronic musculoskeletal conditions

Dosage forms

• Subcutaneous injection

Typical compounded strengths

• 2 mg to 5 mg weekly

AOD-9604

Primary uses

• Fat metabolism• Weight management• Metabolic syndrome

Potential patients

• Weight loss programs• Obesity management clinics

Dosage forms

• Subcutaneous injections• Oral capsules

Typical dosing

• 250 mcg – 500 mcg daily

GHK-Cu (Copper Peptide)

Primary uses

• Skin regeneration• Hair growth• Anti-aging dermatology

Dosage forms

• Topical serums• Injectable formulations• Hair restoration solutions

Typical strengths

• 0.1% – 1% topical• 2 mg injection formulations

Epitalon

Primary uses

• Longevity research• Sleep regulation• Melatonin modulation

Dosage forms

• Subcutaneous injection

Typical dosing

• 5 mg – 10 mg daily for 10–20 day cycles

KPV

Primary uses

• Anti-inflammatory effects• GI inflammation support• Dermatologic inflammation

Dosage forms

• Oral capsules• Topical creams• Subcutaneous injections

Typical strengths

• 250 mcg capsules• 0.5% topical formulations

MOTS-C

Primary uses

• Metabolic regulation• Insulin sensitivity• Mitochondrial function

Potential patients

• Metabolic syndrome• Pre-diabetes• weight loss support

Dosage forms

• Subcutaneous injections

Typical dosing

• 5 mg – 10 mg two to three times weekly

Semax

Primary uses

• Cognitive enhancement• Neuroprotection• Memory and focus support

Dosage forms

• Intranasal spray• Subcutaneous injection

Typical dosing

• 300 mcg – 600 mcg per dose

Selank

Primary uses

• Anxiety modulation• Cognitive support• Stress management

Dosage forms

• Intranasal spray• Subcutaneous injection

Typical dosing

• 250 mcg – 500 mcg per dose

Kisspeptin-10

Primary uses

• Hormonal signaling• Fertility support• Hypothalamic-pituitary-gonadal axis modulation

Dosage forms

• Subcutaneous injection

Typical dosing

• 100 mcg – 200 mcg per injection

GHRP-6

Primary uses

• Growth hormone stimulation• Muscle recovery• Appetite regulation

Dosage forms

• Subcutaneous injection

Typical dosing

• 100 mcg – 300 mcg per injection

Emideltide (DSIP)

Primary uses

• Sleep regulation• Stress modulation

Dosage forms

• Subcutaneous injection

Typical dosing

• 100 mcg – 300 mcg before sleep

PEG-MGF

Primary uses

• Muscle repair• Tissue regeneration• Recovery from intense exercise

Dosage forms

• Subcutaneous injection

Typical dosing

• 200 mcg – 400 mcg post-exercise or injury

Strategic Opportunity for Community Pharmacies

If these peptides return to Category 1, pharmacies have an opportunity to expand into several emerging clinical service areas.

1. Metabolic Health Programs

Peptides such as:

• AOD-9604• MOTS-C

can complement existing GLP-1 weight management programs offered by pharmacies.

2. Regenerative Medicine and Injury Recovery

Peptides including:

• BPC-157• TB-500• PEG-MGF

create opportunities to collaborate with:

• sports medicine clinics• orthopedic physicians• physical therapy centers

3. Cognitive Health and Neurology Support

Neuropeptides like:

• Semax• Selank

open opportunities in brain health, focus, and stress management programs.

4. Dermatology and Aesthetic Medicine

Peptides such as:

• GHK-Cu• KPV

can be compounded into topical dermatologic therapies and hair restoration products.

5. Immune System Support

Thymosin Alpha-1 represents a potential area for collaboration with:

• functional medicine providers• integrative medicine physicians• oncology support clinics

The Role of Pharmacists in Patient Safety

The most important aspect of this regulatory shift is patient safety.

When these therapies are compounded within licensed pharmacies:

• APIs are sourced from verified manufacturers• Certificates of Analysis are reviewed• dosing accuracy is controlled• pharmacists counsel patients• physicians supervise therapy

Without regulated pharmacy access, demand often moves toward unregulated online peptide markets, where product quality and safety cannot be assured.

Keeping therapies within the healthcare system protects patients.

Looking Ahead

If the FDA moves these peptides into Category 1, the compounding pharmacy landscape could change significantly.

For community pharmacies willing to invest in:

• clinical education• physician partnerships• telehealth collaboration• high-quality compounding processes peptide therapy may represent a new category of personalized medicine services.

The pharmacies that succeed will not treat peptides as a commodity.

They will build structured clinical programs around safety, physician collaboration, and pharmacist expertise.

And that is where community pharmacy can once again demonstrate its greatest value—delivering personalized care where commercial medicine often falls short.

Peptides